Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™)Ulrich Costabel, HR Collard, RM du Bois et al.|Pneumologie|2015Cited by 32